I received the following abstract from WE MOVE, which talks about the
interaction between seligiline (eldepryl) and birth control pills or
estrogen replacement therapy. The first 4 paragraphs are not very
understandable - maybe someone with a medical background would be able to
translate - but the last section :" The authors note:" suggests that
according to this study the two should not be taken together, or if they
are, the seligiline dosage should be reduced. Does anyone know any more
about this?
I'm also forwarding a report on recent research on ERT and Parkinson's
found on "The Doctor's Guide to the Internet" It's a good summary and
written in plain English. It seems the research on these topics are just
beginning to get some recognition, and no definite conclusions have been
made yet, but at least it's a start.
Linda
--------- Forwarded message ----------
From: WE MOVE <[log in to unmask]>
Date: Thu, 20 May 1999 16:47:52 -0700
Subject: PD: Estrogen; drug interactions
Dose linearity study of selegiline pharmacokinetics after oral
administration: Evidence for strong drug interaction with female sex
hormones
K Laine, M Anttila, H Karnani, R Huuponen
J Clin Pharmacol 1999;47:249-254
Serum levels of selegiline are greatly increased in women receiving sex
steroid therapy, according to this report.
Eight young women, four of whom were on oral contraceptives, each
received escalating single doses of selegiline (5, 10, 20, or 40 mg,
with at least a two-week washout between doses) followed by five hours
of serum monitoring for selegiline and its metabolite,
desmethylselegiline.
Results showed that for steroid users:
—The area under the time vs. concentration curve (AUC) for selegiline
was significantly greater at all doses. At the 10 mg dose, the AUC was
20 times as large.
—The median maximum serum concentration was more than 10 times as high.
—Time to maximum concentration was not affected.
Much smaller differences were found between users and nonusers in the
AUC for desmethylselegiline, and no differences for other parameters,
suggesting the mechanism of the interaction between oral female sex
steroids and selegiline is inhibition of N-demethylation of selegiline
to desmethylselegiline.
The authors note, "The present results suggest that concomitant use of
selegiline with exogenous female sex steroids should be avoided or the
dosage of selegiline should be reduced in order to minimize the risk of
selegiline-related adverse drug reactions." They note that while
concomitant use of selegiline and oral contraceptive use is unlikely,
hormone replacement therapy may involve even higher daily doses of
hormones.
E-MOVE archives, plus information on subscribing, are
available at http://www.wemove.org/em_intro.html.
To unsubscribe, send an e-mail to [log in to unmask],
with "unsubscribe e-move" in the message body.
E-MOVE is a service of WE MOVE (Worldwide Education and Awareness for
Movement Disorders)
204 West 84th Street
New York, NY 10024
TEL 800-437-MOV2
TEL 212-241-8567
FAX 212-987-7363
http://www.wemove.org
